GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » 5-Year Yield-on-Cost %

Hangzhou Tigermed Consulting Co (HKSE:03347) 5-Year Yield-on-Cost % : 7.16 (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co 5-Year Yield-on-Cost %?

Hangzhou Tigermed Consulting Co's yield on cost for the quarter that ended in Sep. 2024 was 7.16.


The historical rank and industry rank for Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % or its related term are showing as below:

HKSE:03347' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.54   Med: 1.51   Max: 7.16
Current: 7.16


During the past 13 years, Hangzhou Tigermed Consulting Co's highest Yield on Cost was 7.16. The lowest was 0.54. And the median was 1.51.


HKSE:03347's 5-Year Yield-on-Cost % is ranked better than
65.67% of 67 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.97 vs HKSE:03347: 7.16

Competitive Comparison of Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost %

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % falls into.



Hangzhou Tigermed Consulting Co 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Hangzhou Tigermed Consulting Co is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Hangzhou Tigermed Consulting Co  (HKSE:03347) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Hangzhou Tigermed Consulting Co 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Sands Capital Management, Llc 2101 Beneficial owner
Sands Capital Management, Lp 2201 Interest of corporation controlled by you
Sands Family Trust, Llc 2201 Interest of corporation controlled by you
Sands Frank Melville Jr. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
F-j Sands Family I, Llc 2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd 2102 Investment manager
Ninety One Uk Limited 2102 Investment manager
Baillie Gifford & Co 2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines